Search > Diabetes Mellitus
My employer runs this trial

Zenagamtide for Type 2 Diabetes

(AMBITION 1 Trial)

Not yet recruiting at 47 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Novo Nordisk A/S
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

Who Is on the Research Team?

CT

Clinical Transparency (dept. 2834)

Principal Investigator

Novo Nordisk A/S

Are You a Good Fit for This Trial?

This trial is for adults with type 2 diabetes who are managing their condition through diet and exercise. People using other diabetes medications or with certain health issues may not be able to join.

Inclusion Criteria

I was diagnosed with type 2 diabetes at least 30 days ago.
My sex assigned at birth is male or female.
I am 18 years old or older.
See 1 more

Exclusion Criteria

I have not had a recent heart attack, stroke, or serious heart issues in the past 60 days.
I am scheduled for a procedure to restore blood flow in my arteries.
I am currently or have previously been treated with diabetes medications, except insulin for gestational diabetes.
See 4 more

What Are the Treatments Tested in This Trial?

Trial Overview

The study compares a new medicine called zenagamtide to a placebo (inactive treatment) in people with type 2 diabetes. Participants are randomly assigned to receive either the real drug or placebo.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: ZenagamtideExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novo Nordisk A/S

Lead Sponsor

Trials
1,578
Recruited
3,813,000+
Lars Fruergaard Jørgensen profile image

Lars Fruergaard Jørgensen

Novo Nordisk A/S

Chief Executive Officer since 2017

MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark

Martin Holst Lange profile image

Martin Holst Lange

Novo Nordisk A/S

Chief Medical Officer since 2021

MD from University of Copenhagen

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.